3 Benefits Of Centralizing Global Content Solutions For Regulatory Teams

Due to the evolving regulatory landscape, pharmaceutical companies have been forced to adapt their strategies for compliance and meet all requirements. Of those changes, most notably the remote shift after COVID-19, regulatory teams have embraced digitization, which has been shown to reduce submission times, improve collaboration, and enhance visibility into the regulatory process. While this has brought a host of unfamiliar complexities and challenges, it has enabled teams to reduce submission times, work more collaboratively, and increase visibility into all stages of the regulatory process. For example, the EU Clinical Trials Regulation (EU CTR) and Annex VI's impact on IMP labeling workflows are key topics in the regulatory field, aiming to enhance trial safety and efficiency.

With the increasing pressure to handle larger volumes of regulatory materials within tight deadlines, digitization, process automation, and centralization has become crucial for successful submissions. As datasets become more complex, further digitization and optimization are expected in the industry.

As global regulators continue to harmonize, research suggests that by 2025, regulatory authorities will achieve coordination at both national and international levels. This coordination aims to streamline the submission process and address security risks. In the meantime, learning how to prioritize the use of technology frameworks to centralize and manage multiple submissions will help organizations stay aligned with this evolving regulatory landscape. Read about three benefits of centralizing global content solutions in this article focusing on meeting regulatory requirements in clinical trials.